TFX Investors, You Need to Know These Facts Today.

Large-cap Healthcare company Teleflex has moved -5.4% so far today on a volume of 326,062, compared to its average of 404,412. In contrast, the S&P 500 index moved 0.5%.

Teleflex trades -6.66% away from its average analyst target price of $262.92 per share. The 13 analysts following the stock have set target prices ranging from $215 to $330, and on average have given Teleflex a rating of buy.

Anyone interested in buying TFX should be aware of the facts below:

  • Teleflex's current price is 90.9% above its Graham number of $128.55, which implies that at its current valuation it does not offer a margin of safety

  • Teleflex has moved -22.5% over the last year, and the S&P 500 logged a change of -17.1%

  • Based on its trailing earnings per share of 8.71, Teleflex has a trailing 12 month Price to Earnings (P/E) ratio of 28.2 while the S&P 500 average is 15.97

  • TFX has a forward P/E ratio of 18.2 based on its forward 12 month price to earnings (EPS) of $13.5 per share

  • The company has a price to earnings growth (PEG) ratio of 1.9 — a number near or below 1 signifying that Teleflex is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 3.0 compared to its sector average of 4.07

  • Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.

  • Based in Wayne, the company has 14,000 full time employees and a market cap of $11,510,830,080. Teleflex currently returns an annual dividend yield of 0.5%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.